The development of biological valve prostheses with lifetime native-like performance and optimal host engraftment is an ultimate goal of heart valve tissue engineering. We describe a new concept for autologous graft coating based on a CD133+-stem-cells-plus-fibrin (SC+F) complex processed from bone marrow and peripheral blood of a single patient.
Methods:
CD133+-SC (1 × 106 cells/mL) from human bone marrow and autologous fibrin (20 mg/mL) were administered simultaneously via spray administration using the novel Vivostat Co-Delivery System. During static cultivation, SC+F performance was monitored for 20 days after delivery and compared with controls. For dynamic testing SC+F-composite was sprayed on a decellularized porcine pulmonary valve and transferred to a bioreactor under pulsatile flow conditions for 7 days.
Results:
Static cultivation of SC+F-composite induced significant improvements in stem cell proliferation as compared with controls. For dynamic testing, microscopic analyses on a smooth engineered heart valve surface detected homogenous distribution of stem cells. Ultrasonic analysis revealed native-like valve performance. Applied CD133+ stem cells differentiated into endothelial-like cells positive for CD31 and vascular endothelial growth factor receptor 2 and engrafted the valve. However, occasional delamination was observed.
Conclusion:
SC+F serves as an excellent autologous matrix for intraoperative tissue engineering of valve prostheses promising optimal in vivo integration. However, stability remains an issue.
Get full access to this article
View all access options for this article.
References
1.
RabagoG.A worldwide overview of valve usage. RabagoG.Heart Valve Replacement & Future Trends in Cardiac Surgery. New York: Futura Publishing Company, 1987.
2.
JamiesonW.R.Modern cardiac valve devices-bioprostheses and mechanical prostheses: state of the art. J Cardiac Surg, 8:89. 1993.
3.
HammermeisterK.E., SethiG.K., HendersonW.G., OprianC., KimT., RahimtoolaS.A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. N Engl J Med, 18:1289. 1993.
4.
CannegieterS.C., RosendaalF.R., BrietE.Thromboembolic and bleeding complications in patients with mechanical heart valve prosthesis. Circulation, 89:635. 1994.
5.
RajaniB., MeeR.B., RatliffN.B.Evidence for rejection of homograft cardiac heart valves in infants. J Thorac Cardiovasc Surg, 115:111. 1998.
6.
MayerJ.E.Jr.In search of the ideal valve replacement device. J Thorac Cardiovasc Surg, 122:8. 2001.
7.
BrownJ.W., RuzmetovM., RodefeldM.D., VijayP., TurrentineM.W.Right ventricular outflow tract reconstruction with an allograft conduit in non-Ross patients: risk factors for allograft dysfunction and failure. Ann Thorac Surg, 80:655. 2005.
8.
FlanaganT.C., SachwehJ.S., FreseJ., SchnoringH., GronlohN., KochS., TolbaR.H., Schmitz-RodeT., JockenhoevelS.In vivo remodeling and structural characterization of fibrin-based tissue-engineered heart valves in the adult sheep model. Tissue Eng, 15:2965. 2009.
9.
SodianR., HoerstrupS.P., SperlingJ.S., DaebritzS., MartinD.P., MoranA.M., KimB.S., SchoenF.J., VacantiJ.P., MayerJ.E.Jr.Early in vivo experience with tissue-engineered trileaflet heart valves. Circulation, 102:22. 2000.
10.
NehlsV., SchuchardtE., DrenckhahnD.The effect of fibroblasts, vascular smooth muscle cells, and pericytes on sprout formation of endothelial cells in a fibrin gel angiogenesis system. Microvasc Res, 48:349. 1994.
11.
FlanaganT.C., CornelissenC., KochS., TschoekeB., SachwehJ.S., Schmitz-RodeT., JockenhoevelS.The in-vitro development of autologous fibrin-based tissue-engineered heart valves through optimised dynamic conditioning. Biomaterials, 28:3388. 2007.
12.
SyedainZ.H., WeinbergJ.S., TranquilloR.T.Cyclic distension of fibrin-based tissue constructs: evidence of adaptation during growth of engineered connective tissue. Proc Natl Acad Sci U S A, 105:6537. 2008.
13.
RügerB.M., BreussJ., HollemannD., YanagidaG., FischerM.B., MosbergerI., ChottA., LangI., DavisP.F., HöckerP., DettkeM.Vascular morphogenesis by adult bone marrow progenitor cells in three-dimensional fibrin matrices. Differentiation, 76:772. 2008.
14.
MaN., LadilovY., MoebiusJ.M., OngL., PiechaczekC., DávidA., KaminskiA., ChoiY.H., LiW., EggerD., StammC., SteinhoffG.Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: bone marrow vs. cord blood-derived cells. Cardiovasc Res, 71:158. 2006.
15.
GrieseD.P., EhsanA., MeloL.G., KongD., ZhangL., MannM.J., PrattR.E., MulliganR.C., DzauV.J.Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation, 108:2710. 2003.
FlanaganT.C., CornelissenC., KochS., TschoekeB., SachwehJ.S., Schmitz-RodeT., JockenhoevelS.The in-vitro development of autologous fibrin-based tissue-engineered heart valves through optimised dynamic conditioning. Biomaterials, 28:3388. 2007.
20.
Last'ovickaJ., BudinskýV., SpísekR., BartůnkováJ.Assessment of lymphocyte proliferation: CFSE kills dividing cells and modulates expression of activation markers. Cell Immunol, 256:79. 2009.
21.
HuchK., StöveJ., PuhlW., GüntherK.P.Review and comparison of culture-techniques for articular chondrocytes. Z Orthop Ihre Grenzgeb, 140:145. 2002.
22.
Al-LamkiR.S., BradleyJ.R., PoberJ.S.Endothelial cells in allograft rejection. Transplantation, 86:1340. 2008.
23.
UrbichC., DimmelerS.Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int, 67:1672. 2005.
24.
JockenhoevelS., ZundG., HoerstrupS.P., ChalabiK., SachwehJ.S., DemircanL., MessmerB.J., TurinaM.Fibrin gel–advantages of a new scaffold in cardiovascular tissue engineering. Eur J Cardiothorac Surg, 19:424. 2001.
25.
GrantI., WarwickK., MarshallJ., GreenC., MartinR.The co-application of sprayed cultured autologous keratinocytes and autologous fibrin sealant in a porcine wound model. Br J Plast Surg, 55:219. 2002.
26.
EngelseM.A., LaurensN., VerloopR.E., KoolwijkP., van HinsberghV.W.Differential gene expression analysis of tubule forming and non-tubule forming endothelial cells: CDC42GAP as a counter-regulator in tubule formation. Angiogenesis, 11:153. 2008.
27.
NehlsV., SchuchardtE., DrenckhahnD.The effect of fibroblasts, vascular smooth muscle cells, and pericytes on sprout formation of endothelial cells in a fibrin gel angiogenesis system. Microvasc Res, 48:349. 1994.
28.
van HinsberghV.W., CollenA., KoolwijkP.Role of fibrin matrix in angiogenesis. Ann N Y Acad Sci, 936:426. 2001.
29.
UrbichC., DimmelerS.Endothelial progenitor cells: characterization and role in vascular biology. Circ Res, 95:343. 2004.
30.
MizrakD., BrittanM., AlisonM.R.CD133: molecule of the moment. J Pathol, 214:3. 2008.
31.
LeoneA.M., ValgimigliM., GiannicoM.B., ZacconeV., PerfettiM., D'AmarioD., RebuzziA.G., CreaF.From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells. Eur Heart J, 30:890. 2009.
32.
KlopschC., FurlaniD., GäbelR., LiW., PittermannE., UgurlucanM., KundtG., ZinglerC., TitzeU., WangW., OngL.L., WagnerK., LiR.K., MaN., SteinhoffG.Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model. J Cell Mol Med, 13:664. 2009.
33.
YamamotoK., TakahashiT., AsaharaT., OhuraN., SokabeT., KamiyaA., AndoJ.Proliferation, differentiation, and tube formation by endothelial progenitor cells in response to shear stress. J Appl Physiol, 95:2081. 2003.
34.
BuchtaC., HedrichH.C., MacherM., HöckerP., RedlH.Biochemical characterization of autologous fibrin sealants produced by CryoSeal and Vivostat in comparison to the homologous fibrin sealant product Tissucol/Tisseel. Biomaterials, 26:6233. 2005.
35.
HorvathK.A., BerryG.J.ICEM Investigators. The incidence of emboli during cardiac surgery: a histopathologic analysis of 2297 patients. Heart Surg Forum, 8:61. 2005.
36.
FurstW., BanerjeeA., RedlH.Comparison of structure, strength and cytocompatibility of a fibrin matrix supplemented either with tranexamic acid or aprotinin. J Biomed Mater Res B Appl Biomater, 82:109. 2007.
37.
CholewinskiE., DietrichM., FlanaganT.C., Schmitz-RodeT., JockenhoevelS.Tranexamic acid—an alternative to aprotinin in fibrin-based cardiovascular tissue engineering. Tissue Eng Part A, 15:3645. 2009.
SchlagM.G., HopfR., RedlH.Hind limb hyperexcitability following the application of fibrin sealants containing tranexamic acid to the lumbar spinal cord in rats. Eur J Trauma, 68:1125. 2004.
40.
KoolwijkP., van ErckM.G., de VreeW.J., VermeerM.A., WeichH.A., HanemaaijerR., van HinsberghV.W.Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol, 132:1177. 1996.
41.
PaulD., SamuelS.M., MaulikN.Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration. Antioxid Redox Signal, 11:1841. 2009.
